ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
66.862,23
2,49%
Brent Oil
83,76
0,67%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Albireo Pharma Inc (ALBO)

  7. Albireo Pharma Inc (ALBO) Notícias

ALBO

Albireo Pharma (ALBO)

Albireo Pharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALBO
DataHoraFonteTítuloCódigoCompanhia
14/02/202410:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALBOAlbireo Pharma Inc
09/03/202308:14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALBOAlbireo Pharma Inc
03/03/202308:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:53Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:49Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202318:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202313:29Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202313:24Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ALBOAlbireo Pharma Inc
27/02/202318:06Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202318:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202310:30GlobeNewswire Inc.FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeNASDAQ:ALBOAlbireo Pharma Inc
27/01/202319:29Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ALBOAlbireo Pharma Inc
23/01/202310:13Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ALBOAlbireo Pharma Inc
19/01/202318:12Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:ALBOAlbireo Pharma Inc
10/01/202308:07Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ALBOAlbireo Pharma Inc
21/12/202218:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALBOAlbireo Pharma Inc
20/12/202218:30GlobeNewswire Inc.Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALBOAlbireo Pharma Inc
19/12/202210:30GlobeNewswire Inc.Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMANASDAQ:ALBOAlbireo Pharma Inc
08/12/202214:35TipRanksWedbush Reaffirms Their Buy Rating on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
06/12/202210:30GlobeNewswire Inc.Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNASDAQ:ALBOAlbireo Pharma Inc
09/11/202210:30GlobeNewswire Inc.Albireo to Participate in Jefferies London Healthcare ConferenceNASDAQ:ALBOAlbireo Pharma Inc
09/11/202208:46TipRanksWedbush Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
09/11/202208:35TipRanksH.C. Wainwright Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202218:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202218:01GlobeNewswire Inc.Albireo Reports Q3 2022 Financial Results and Business UpdateNASDAQ:ALBOAlbireo Pharma Inc
07/11/202210:30GlobeNewswire Inc.Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNASDAQ:ALBOAlbireo Pharma Inc
03/11/202209:30GlobeNewswire Inc.Albireo Announces 2022 SPARK Grant WinnersNASDAQ:ALBOAlbireo Pharma Inc
02/11/202209:30GlobeNewswire Inc.Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNASDAQ:ALBOAlbireo Pharma Inc
01/11/202209:30GlobeNewswire Inc.Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022NASDAQ:ALBOAlbireo Pharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALBO

Seu Histórico Recente

ASX
FXRN
NASDAQ
FCAAX
First Eagle Credit Oppor...
USOTC
APRM
American Pacific Rim Com... (CE)
USOTC
HMZMF
HMZ Metals (GM)
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados